查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
糞便鈣蛋白檢測市場（患者類型：成人和兒科；檢測類型：ELISA、酶聯免疫法和定量免疫層析法） - 2023-2031年全球行業分析、規模、佔有率、成長、趨勢和預測
市場調查報告書
商品編碼
1301433

糞便鈣蛋白檢測市場（患者類型：成人和兒科；檢測類型：ELISA、酶聯免疫法和定量免疫層析法） - 2023-2031年全球行業分析、規模、佔有率、成長、趨勢和預測

Fecal Calprotectin Test Market (Patient Type: Adult and Pediatric; Assay Type: ELISA, Enzyme Fluoroimmunoassay, and Quantitative Immune-chromatography) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 203 Pages | 商品交期: 2-10個工作天內

價格

糞便鈣蛋白檢測儀市場- 報告範圍

TMR關於全球糞便鈣蛋白檢測市場的報告研究了過去以及當前的成長趨勢和機會，以獲得對2023年至2031年預測期間市場指標的寶貴見解。報告提供了2017-2031年期間全球糞便鈣蛋白檢測市場的收入，考慮到2023年為基準年，2031年為預測年。報告還提供了2023年至2031年全球糞便鈣蛋白檢測市場的複合年成長率（CAGR %）。

該報告是在廣泛研究後編寫的。一級研究涉及大部分的研究工作，其中分析師與關鍵意見領袖、行業領袖和意見製造者進行了訪談。二級研究包括參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解糞便鈣蛋白檢測市場。

該報告深入研究了全球糞便鈣蛋白檢測市場的競爭格局。已經確定了在全球糞便鈣蛋白檢測市場運作的主要參與者，並對其中每一個參與者的各種屬性進行了分析。公司概況、財務狀況、近期發展和SWOT是本報告中介紹的全球糞便鈣蛋白檢測市場參與者的屬性。

目錄

第一章：前言

  • 市場定義和範圍
  • 市場細分
  • 主要研究目標
  • 研究重點

第二章：假設和研究方法

第三章：執行摘要：全球市場

第四章：市場概述

  • 簡介
    • 病人類型的定義
    • 行業演變/發展
  • 概述
  • 市場動態
    • 驅動力
    • 限制因素
    • 機會
  • 2017-2031年全球市場分析和預測
    • 市場收入預測

第5章：關鍵洞察力

  • 技術進步
  • 疾病流行病學
  • 監管情況
  • 價格分析
  • COVID-19影響分析

第六章：全球市場分析與預測：按病人類型分類

  • 介紹和定義
  • 主要研究結果/發展情況
  • 市場價值預測：按病人類型，2017-2031年
    • 成人
    • 兒科
  • 市場吸引力分析：按病人類型

第7章：全球市場分析與預測：按檢測類型分類

  • 介紹和定義
  • 主要研究結果/發展情況
  • 市場價值預測：按檢測類型，2017-2031年
    • ELISA（酶聯免疫吸附法）
    • 酶聯免疫分析法（Enzyme Fluoroimmunoassay
    • 定量免疫層析法
  • 市場吸引力分析：按檢測類型

第八章：全球市場分析與預測：按適應症分類

  • 介紹和定義
  • 主要研究結果/發展情況
  • 市場價值預測：按適應症分類，2017-2031年
    • 炎症性腸病
    • 結直腸癌
    • 乳糜瀉
  • 市場吸引力分析：按適應症分類

第九章：全球市場分析與預測：按終端用戶分類

  • 介紹和定義
  • 主要研究結果/發展情況
  • 市場價值預測：按終端用戶，2017-2031年
    • 醫院
    • 診斷實驗室
    • 學術和研究機構
  • 市場吸引力分析：按終端用戶分類

第十章：全球市場分析與預測：按地區分類

  • 主要發現
  • 市場價值預測：按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第11章：北美洲市場分析與預測

  • 簡介
    • 主要研究結果
  • 市場價值預測：按病人類型，2017-2031年
    • 成人
    • 兒科
  • 市場價值預測：按檢測類型，2017-2031年
    • ELISA（酶聯免疫吸附法）
    • 酶聯免疫分析法（Enzyme Fluoroimmunoassay
    • 定量免疫層析法
  • 市場價值預測：按適應症分類，2017-2031年
    • 炎症性腸病
    • 結直腸癌
    • 腹腔疾病
  • 市場價值預測：按終端用戶，2017-2031年
    • 醫院
    • 診斷實驗室
    • 學術和研究機構
  • 市場價值預測：按國家分類，2017-2031年
    • 美國
    • 加拿大
  • 市場吸引力分析
    • 按病人類型
    • 按化驗類型
    • 按適應症分類
    • 按終端用戶分類
    • 按國家分類

第12章：歐洲市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按病人類型，2017-2031年
    • 成人
    • 兒科
  • 市場價值預測：按檢測類型，2017-2031年
    • ELISA（酶聯免疫吸附法）
    • 酶聯免疫分析法（Enzyme Fluoroimmunoassay
    • 定量免疫層析法
  • 市場價值預測：按適應症分類，2017-2031年
    • 炎症性腸病
    • 結直腸癌
    • 腹腔疾病
  • 市場價值預測：按終端用戶，2017-2031年
    • 醫院
    • 診斷實驗室
    • 學術和研究機構
  • 市場價值預測：按國家/次區域，2017-2031年
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 市場吸引力分析
    • 按病人類型
    • 按檢測類型
    • 按適應症分類
    • 按終端用戶
    • 按國家/次區域分類

第13章：亞太地區市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按病人類型，2017-2031年
    • 成人
    • 兒科
  • 市場價值預測：按檢測類型，2017-2031年
    • ELISA（酶聯免疫吸附法）
    • 酶聯免疫分析法（Enzyme Fluoroimmunoassay
    • 定量免疫層析法
  • 市場價值預測：按適應症分類，2017-2031年
    • 炎症性腸病
    • 結直腸癌
    • 腹腔疾病
  • 市場價值預測：按終端用戶，2017-2031年
    • 醫院
    • 診斷實驗室
    • 學術和研究機構
  • 市場價值預測：按國家/次區域，2017-2031年
    • 中國
    • 日本
    • 印度
    • 澳大利亞和新西蘭
    • 亞太其他地區
  • 市場吸引力分析
    • 按病人類型
    • 按檢測類型
    • 按適應症分類
    • 按終端用戶
    • 按國家/次區域分類

第十四章：拉丁美洲市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按病人類型，2017-2031年
    • 成人
    • 兒科
  • 市場價值預測：按檢測類型，2017-2031年
    • ELISA（酶聯免疫吸附法）
    • 酶聯免疫分析法（Enzyme Fluoroimmunoassay
    • 定量免疫層析法
  • 市場價值預測：按適應症分類，2017-2031年
    • 炎症性腸病
    • 結直腸癌
    • 腹腔疾病
  • 市場價值預測：按終端用戶，2017-2031年
    • 醫院
    • 診斷實驗室
    • 學術和研究機構
  • 市場價值預測：按國家/次區域，2017-2031年
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 市場吸引力分析
    • 按病人類型
    • 按檢測類型
    • 按適應症分類
    • 按終端用戶
    • 按國家/次區域分類

第15章：中東和非洲市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按病人類型，2017-2031年
    • 成人
    • 兒科
  • 市場價值預測：按檢測類型，2017-2031年
    • ELISA（酶聯免疫吸附法）
    • 酶聯免疫分析法（Enzyme Fluoroimmunoassay
    • 定量免疫層析法
  • 市場價值預測：按適應症分類，2017-2031年
    • 炎症性腸病
    • 結直腸癌
    • 腹腔疾病
  • 市場價值預測：按終端用戶，2017-2031年
    • 醫院
    • 診斷實驗室
    • 學術和研究機構
  • 市場價值預測：按國家/次區域，2017-2031年
    • 海灣合作理事會國家
    • 南非
    • 中東和非洲其他地區
  • 市場吸引力分析
    • 按病人類型
    • 按化驗類型
    • 按適應症分類
    • 按終端用戶
    • 按國家/次區域分類

第16章：競爭格局

  • 市場參與者- 競爭矩陣（按公司層級和規模）。
  • 市場佔有率分析：按公司分類(2022)
  • 公司簡介
    • Abbexa
    • ALPCO
    • Alpha Laboratories
    • Biomerica
    • BUHLMANN Laboratories AG
    • DRG Instruments GmbH
    • EagleBio
    • Epitope Diagnostics, Inc.
    • OPERON, SA
    • R-Biopharm AG
    • Svar Life Science
    • Thermo Fisher Scientific, Inc.
    • Werfen
    • SENTINEL CH. SpA
    • Diazyme Laboratories, Inc.
    • DiAgam
Product Code: TMRGL78383

Fecal Calprotectin Test Market - Scope of Report

TMR's report on the global Fecal Calprotectin Test market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Fecal Calprotectin Test market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Fecal Calprotectin Test market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Fecal Calprotectin Test market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Fecal Calprotectin Test market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Fecal Calprotectin Test market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Fecal Calprotectin Test market.

The report delves into the competitive landscape of the global Fecal Calprotectin Test market. Key players operating in the global Fecal Calprotectin Test market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Fecal Calprotectin Test market profiled in this report.

Key Questions Answered in Global Fecal Calprotectin Test Market Report:

  • What is the sales/revenue generated by Fecal Calprotectin Test across all regions during the forecast period?
  • What are the opportunities in the global Fecal Calprotectin Test market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Fecal Calprotectin Test Market - Research Objectives and Research Approach

The comprehensive report on the global Fecal Calprotectin Test market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Fecal Calprotectin Test market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Fecal Calprotectin Test market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fecal Calprotectin Test Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Patient Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Fecal Calprotectin Test Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Advancement
  • 5.2. Diseases Epidemiology
  • 5.3. Regulatory Scenario
  • 5.4. Pricing Analysis
  • 5.5. COVID-19 Impact Analysis

6. Global Fecal Calprotectin Test Market Analysis and Forecast, by Patient Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Patient Type, 2017-2031
    • 6.3.1. Adult
    • 6.3.2. Pediatric
  • 6.4. Market Attractiveness Analysis, by Patient Type

7. Global Fecal Calprotectin Test Market Analysis and Forecast, by Assay Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Assay Type, 2017-2031
    • 7.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 7.3.2. Enzyme Fluoroimmunoassay
    • 7.3.3. Quantitative Immune-chromatography
  • 7.4. Market Attractiveness Analysis, by Assay Type

8. Global Fecal Calprotectin Test Market Analysis and Forecast, by Indication

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Indication, 2017-2031
    • 8.3.1. Inflammatory Bowel Disease
    • 8.3.2. Colorectal Cancer
    • 8.3.3. Celiac Disease
  • 8.4. Market Attractiveness Analysis, by Indication

9. Global Fecal Calprotectin Test Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Hospitals
    • 9.3.2. Diagnostic Laboratories
    • 9.3.3. Academic & Research Institutes
  • 9.4. Market Attractiveness Analysis, by End-user

10. Global Fecal Calprotectin Test Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Region

11. North America Fecal Calprotectin Test Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Patient Type, 2017-2031
    • 11.2.1. Adult
    • 11.2.2. Pediatric
  • 11.3. Market Value Forecast, by Assay Type, 2017-2031
    • 11.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 11.3.2. Enzyme Fluoroimmunoassay
    • 11.3.3. Quantitative Immune-chromatography
  • 11.4. Market Value Forecast, by Indication, 2017-2031
    • 11.4.1. Inflammatory Bowel Disease
    • 11.4.2. Colorectal Cancer
    • 11.4.3. Celiac Disease
  • 11.5. Market Value Forecast, by End-user, 2017-2031
    • 11.5.1. Hospitals
    • 11.5.2. Diagnostic Laboratories
    • 11.5.3. Academic & Research Institutes
  • 11.6. Market Value Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Patient Type
    • 11.7.2. By Assay Type
    • 11.7.3. By Indication
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Fecal Calprotectin Test Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Patient Type, 2017-2031
    • 12.2.1. Adult
    • 12.2.2. Pediatric
  • 12.3. Market Value Forecast, by Assay Type, 2017-2031
    • 12.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 12.3.2. Enzyme Fluoroimmunoassay
    • 12.3.3. Quantitative Immune-chromatography
  • 12.4. Market Value Forecast, by Indication, 2017-2031
    • 12.4.1. Inflammatory Bowel Disease
    • 12.4.2. Colorectal Cancer
    • 12.4.3. Celiac Disease
  • 12.5. Market Value Forecast, by End-user, 2017-2031
    • 12.5.1. Hospitals
    • 12.5.2. Diagnostic Laboratories
    • 12.5.3. Academic & Research Institutes
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Patient Type
    • 12.7.2. By Assay Type
    • 12.7.3. By Indication
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Fecal Calprotectin Test Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Patient Type, 2017-2031
    • 13.2.1. Adult
    • 13.2.2. Pediatric
  • 13.3. Market Value Forecast, by Assay Type, 2017-2031
    • 13.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 13.3.2. Enzyme Fluoroimmunoassay
    • 13.3.3. Quantitative Immune-chromatography
  • 13.4. Market Value Forecast, by Indication, 2017-2031
    • 13.4.1. Inflammatory Bowel Disease
    • 13.4.2. Colorectal Cancer
    • 13.4.3. Celiac Disease
  • 13.5. Market Value Forecast, by End-user, 2017-2031
    • 13.5.1. Hospitals
    • 13.5.2. Diagnostic Laboratories
    • 13.5.3. Academic & Research Institutes
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Patient Type
    • 13.7.2. By Assay Type
    • 13.7.3. By Indication
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Fecal Calprotectin Test Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Patient Type, 2017-2031
    • 14.2.1. Adult
    • 14.2.2. Pediatric
  • 14.3. Market Value Forecast, by Assay Type, 2017-2031
    • 14.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 14.3.2. Enzyme Fluoroimmunoassay
    • 14.3.3. Quantitative Immune-chromatography
  • 14.4. Market Value Forecast, by Indication, 2017-2031
    • 14.4.1. Inflammatory Bowel Disease
    • 14.4.2. Colorectal Cancer
    • 14.4.3. Celiac Disease
  • 14.5. Market Value Forecast, by End-user, 2017-2031
    • 14.5.1. Hospitals
    • 14.5.2. Diagnostic Laboratories
    • 14.5.3. Academic & Research Institutes
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Patient Type
    • 14.7.2. By Assay Type
    • 14.7.3. By Indication
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Fecal Calprotectin Test Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Patient Type, 2017-2031
    • 15.2.1. Adult
    • 15.2.2. Pediatric
  • 15.3. Market Value Forecast, by Assay Type, 2017-2031
    • 15.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 15.3.2. Enzyme Fluoroimmunoassay
    • 15.3.3. Quantitative Immune-chromatography
  • 15.4. Market Value Forecast, by Indication, 2017-2031
    • 15.4.1. Inflammatory Bowel Disease
    • 15.4.2. Colorectal Cancer
    • 15.4.3. Celiac Disease
  • 15.5. Market Value Forecast, by End-user, 2017-2031
    • 15.5.1. Hospitals
    • 15.5.2. Diagnostic Laboratories
    • 15.5.3. Academic & Research Institutes
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Patient Type
    • 15.7.2. By Assay Type
    • 15.7.3. By Indication
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competitive Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company (2022)
  • 16.3. Company Profiles
    • 16.3.1. Abbexa
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Drug Class Portfolio
      • 16.3.1.3. SWOT Analysis
      • 16.3.1.4. Financial Overview
      • 16.3.1.5. Strategic Overview
    • 16.3.2. ALPCO
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Drug Class Portfolio
      • 16.3.2.3. SWOT Analysis
      • 16.3.2.4. Financial Overview
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Alpha Laboratories
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Drug Class Portfolio
      • 16.3.3.3. SWOT Analysis
      • 16.3.3.4. Financial Overview
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Biomerica
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Drug Class Portfolio
      • 16.3.4.3. SWOT Analysis
      • 16.3.4.4. Financial Overview
      • 16.3.4.5. Strategic Overview
    • 16.3.5. BUHLMANN Laboratories AG
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Drug Class Portfolio
      • 16.3.5.3. SWOT Analysis
      • 16.3.5.4. Financial Overview
      • 16.3.5.5. Strategic Overview
    • 16.3.6. DRG Instruments GmbH
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Drug Class Portfolio
      • 16.3.6.3. SWOT Analysis
      • 16.3.6.4. Financial Overview
      • 16.3.6.5. Strategic Overview
    • 16.3.7. EagleBio
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Drug Class Portfolio
      • 16.3.7.3. SWOT Analysis
      • 16.3.7.4. Financial Overview
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Epitope Diagnostics, Inc.
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Drug Class Portfolio
      • 16.3.8.3. SWOT Analysis
      • 16.3.8.4. Financial Overview
      • 16.3.8.5. Strategic Overview
    • 16.3.9. OPERON, S.A.
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Drug Class Portfolio
      • 16.3.9.3. SWOT Analysis
      • 16.3.9.4. Financial Overview
      • 16.3.9.5. Strategic Overview
    • 16.3.10. R-Biopharm AG
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Drug Class Portfolio
      • 16.3.10.3. SWOT Analysis
      • 16.3.10.4. Financial Overview
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Svar Life Science
      • 16.3.11.1. Company Overview
      • 16.3.11.2. Drug Class Portfolio
      • 16.3.11.3. SWOT Analysis
      • 16.3.11.4. Financial Overview
      • 16.3.11.5. Strategic Overview
    • 16.3.12. Thermo Fisher Scientific, Inc.
      • 16.3.12.1. Company Overview
      • 16.3.12.2. Drug Class Portfolio
      • 16.3.12.3. SWOT Analysis
      • 16.3.12.4. Financial Overview
      • 16.3.12.5. Strategic Overview
    • 16.3.13. Werfen
      • 16.3.13.1. Company Overview
      • 16.3.13.2. Drug Class Portfolio
      • 16.3.13.3. SWOT Analysis
      • 16.3.13.4. Financial Overview
      • 16.3.13.5. Strategic Overview
    • 16.3.14. SENTINEL CH. SpA
      • 16.3.14.1. Company Overview
      • 16.3.14.2. Drug Class Portfolio
      • 16.3.14.3. SWOT Analysis
      • 16.3.14.4. Financial Overview
      • 16.3.14.5. Strategic Overview
    • 16.3.15. Diazyme Laboratories, Inc.
      • 16.3.15.1. Company Overview
      • 16.3.15.2. Drug Class Portfolio
      • 16.3.15.3. SWOT Analysis
      • 16.3.15.4. Financial Overview
      • 16.3.15.5. Strategic Overview
    • 16.3.16. DiAgam
      • 16.3.16.1. Company Overview
      • 16.3.16.2. Drug Class Portfolio
      • 16.3.16.3. SWOT Analysis
      • 16.3.16.4. Financial Overview
      • 16.3.16.5. Strategic Overview

List of Tables

  • Table 01: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 02: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 03: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 04: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 05: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 08: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 09: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 10: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 11: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 13: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 14: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 15: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 16: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 18: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 19: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 20: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 23: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 24: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 25: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 26: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 28: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 29: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 30: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Fecal Calprotectin Test Market Value Share, by Patient Type, 2022
  • Figure 03: Global Fecal Calprotectin Test Market Value Share, by Assay Type, 2022
  • Figure 04: Global Fecal Calprotectin Test Market Value Share, by Indication, 2022
  • Figure 05: Global Fecal Calprotectin Test Market Value Share, by End-user, 2022
  • Figure 06: Global Fecal Calprotectin Test Market Value Share, by Region, 2022
  • Figure 07: Global Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 08: Global Fecal Calprotectin Test Market (US$ Mn), by Adult, 2017-2031
  • Figure 09 Global Fecal Calprotectin Test Market (US$ Mn), by Pediatric, 2017-2031
  • Figure 10: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 11: Global Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 12: Global Fecal Calprotectin Test Market (US$ Mn), by ELISA (Enzyme linked Immunosorbent Assay), 2017-2031
  • Figure 13 Global Fecal Calprotectin Test Market (US$ Mn), by Enzyme Fluoroimmunoassay, 2017-2031
  • Figure 14: Global Fecal Calprotectin Test Market (US$ Mn), by Quantitative Immune-chromatography, 2017-2031
  • Figure 15: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 16: Global Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 17: Global Fecal Calprotectin Test Market (US$ Mn), by Inflammatory Bowel Disease, 2017-2031
  • Figure 18: Global Fecal Calprotectin Test Market (US$ Mn), by Colorectal Cancer, 2017-2031
  • Figure 19: Global Fecal Calprotectin Test Market (US$ Mn), by Celiac Disease, 2017-2031
  • Figure 20: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 21: Global Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 22: Global Fecal Calprotectin Test Market (US$ Mn), by Hospitals, 2017-2031
  • Figure 23: Global Fecal Calprotectin Test Market (US$ Mn), by Diagnostic Laboratories, 2017-2031
  • Figure 24: Global Fecal Calprotectin Test Market (US$ Mn), by Academic & Research Institutes, 2017-2031
  • Figure 25: Global Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 26: Global Fecal Calprotectin Test Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 27: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 28: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 29: North America Fecal Calprotectin Test Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 30: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 31: North America Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 32: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 33: North America Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 34: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 35: North America Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 36: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 37: North America Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 38: North America Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 39: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 40: Europe Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 41: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 42: Europe Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 43: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 44: Europe Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 45: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 46: Europe Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 47: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 48: Europe Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 49: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 50: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 51: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 52: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 53: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 54: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 55: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 56: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 57: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 58: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 51: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 60: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 61: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 62: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 63: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 64: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 65: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 66: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 67: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 68: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 69: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 70: Latin America Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 71: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 72: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 73: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 74: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 75: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 76: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 77: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 78: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 79: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 80: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 81: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 82: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 83: Global Fecal Calprotectin Test Market Share, by Company, 2022